| 体内研究: |
Epertinib hydrochloride (0-100 mg/kg,口服,每天一次,持续 28 天) 显示出抗肿瘤活性。 Epertinib hydrochloride (50 mg/kg,口服,每天一次,持续 30 天) 显著减小脑肿瘤体积。 Epertinib hydrochloride (0-50 mg/kg,口服,每日一次,连续 10-28 天) 呈剂量依赖性显著抑制脑肿瘤生长。 |
| 参考文献: |
1. Tanaka Y, et al. Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity. Sci Rep. 2018 Jan 10;8(1):343. 2. Tanaka H, et al. Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. Cancer Sci. 2014 Aug;105(8):1040-8. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.677 ml |
8.383 ml |
16.765 ml |
| 5 mM |
0.335 ml |
1.677 ml |
3.353 ml |
| 10 mM |
0.168 ml |
0.838 ml |
1.677 ml |
| 50 mM |
0.034 ml |
0.168 ml |
0.335 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |